Rivaroxaban, dabigatran and
apixaban are possibly associated
with a risk of hair loss (alopecia),
according to NZ’s Medsafe, which
has added these NOACs to its
medicines monitoring scheme for
the remainder of this year.
Hair loss is not a known side effect
of the NOACs but does occur with
heparin and warfarin, with Medsafe
saying the overall benefit-risk
balance of rivaroxaban, dabigatran
and apixaban remains positive.The above article was sent to subscribers in Pharmacy Daily's issue from 07 Jun 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Jun 16
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.